August 14th 2025
The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017